Tolvaptan Reduces Body Weight, Improves Congestive Symptoms; Adverse Reactions Seen in Less than 20% of Patients: Interim Analysis of PMS Data

An interim analysis of post-marketing surveillance of the vasopressin V 2 -receptor antagonist tolvaptan (brand name: Samsca) was announced at the 78th Annual Scientific Meeting of the Japanese Circulation Society on March 22. Tolvaptan significantly reduced body weight and improved...read more